Loading…
← CockpitCompetitor Analysis › 006120.KS SK Discovery Co. Ltd.Open in the cockpit ↗

SK Discovery Co. Ltd.006120.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum leader 95
Mkt cap
$866M
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$1.93M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.5 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · KRW₩68,200
1D+2.4%
1W+1.0%
1M-1.0%
3M+29.4%
6M+25.1%
YTD+18.0%
1Y+17.0%
ATR %5.9%
52w lowhigh6.6% off high

What SK Discovery does

Employees: 65

SK Discovery at a glance

Size SK Discovery (006120.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $866M, the 259th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩68,200 on 18 Nov 2026.

Performance Over six months the shares gained 25.1%, against -26.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — highest of 19 in its peer set.

Growth Revenue grew 23.5% over the last twelve months (peer median +1.4%); the operating margin is 2.6% (peer median -0.8%).

Valuation It trades at 0.8× enterprise value to sales against a peer median of 5.8× (cheapest of 18).

Capital Return on invested capital runs 3.5 points below its cost of capital (5.0% WACC).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026006120.KS 126Peer median 75
Six months, rebased to 100: SK Discovery against the median of its 20 peers (local-currency closes).

SK Discovery financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩12.4T₩10.2T₩9.04T₩8.94T₩8.72T
Revenue growth—+12%+1%+3%—
Gross profit₩1.36T₩1.20T₩936B₩963B₩767B
EBITDA₩909B₩884B₩540B₩603B₩543B
Net income₩382B₩129B₩36.5B₩191B₩427B
Free cash flow-₩353B-₩143B-₩774B-₩393B-₩532B
Capital expenditure₩834B₩843B₩833B₩971B₩625B
Total debt₩8.00T₩7.26T₩6.44T₩4.77T₩4.13T

Quarterly statements and history in the cockpit →

SK Discovery competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%600771PHARMSANOFICONR4521CRVS069620086450688176688621000597AKTS6885533002670008136032292595002082IMTX006120.KS6-month return →1-month return →
Up and to the right = strong over both horizons. SK Discovery is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×20×40×60×600771PHARMSANOFICONR4521688176AKTS2595002082006120.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SK Discovery is the large dot.

SK Discovery competitors and peer comparison

How SK Discovery compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SK Discovery against its 20 peers (data as of 18 Nov 2026)
Measure006120.KSPeer medianRank in peer set
1-month return-1.0%-11.6%6th highest of 21
6-month return+25.1%-26.0%highest of 19
Distance from 52-week high-6.6%-43.7%highest of 21
Revenue growth (TTM)+23.5%+1.4%3rd highest of 19
Operating margin2.6%-0.8%9th highest of 19
EV / Sales0.8×5.8×cheapest of 18
ROIC minus cost of capital-3.5 pp-2.3 pp7th lowest of 15
EV / EBITDA11.0×8.8×3rd most expensive of 6
Net debt / EBITDA4.6×-0.9×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a

Questions

Which companies are SK Discovery's closest peers?
The cockpit's peer set: GuangYuYuan Chinese Herbal Medicine (600771.SS), Pharming (PHARM.AS), Sanofi Consumer Healthcare India (SANOFICONR.NS), City Therapeutics (CTY), Kaken Pharmaceutical (4521.T), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS).
Is SK Discovery expensive compared with its peers?
On ev / sales it trades at 0.8× against a peer median of 5.8×, cheapest of 18 in its peer set.
How has SK Discovery stock performed?
Over six months to 18 Nov 2026 the shares returned +25.1% against -26.0% for the median peer; over one year +17.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.